MedTech & Diagnostics

NovoCure Executive Compensation (FY25)

Name: NovoCure (NVCR) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

NVCR · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Frank Leonard

Median of the other named officers

$4,159,945

5 officers, excluding the chief executive

Latest say-on-pay support

June 3, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The paid brief on NovoCure

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $499 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

Data as of October 17, 2026Latest filing (8-K): June 5, 2026

6 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

NovoCure brief$1,500Get the executive brief

Velarion Member, one year

365 figures on this page: 363 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is NovoCure's chief executive and what were they paid?

Total compensation for Frank Leonard, Chief Executive Officer, came to $6,975,329 in fiscal 2025. Leonard's total was 19.8% higher than the $5,823,930 reported for fiscal 2024.

What was NovoCure's say-on-pay result?

Shareholders supported the say-on-pay proposal with 91.0% of votes cast for or against in favor at the meeting held June 3, 2026 for fiscal 2025.

Which companies are in NovoCure's peer group?

Companies named in the disclosed peer group include 10x Genomics, Inc., Align Technology, Alnylam Pharmaceuticals, Inc., CRISPR Therapeutics AG and Exact Sciences Corporation, among others.

What is NovoCure's chief executive pay ratio?

The disclosed chief executive pay ratio for fiscal 2025 is 84:1, against median employee compensation of $148,799.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Ashley Cordova Chief Financial Officer	◇	◇	◇	◇	◇	—	◇	◇
Wilhelmus Groenhuysen Chief Operating Officer	◇	—	◇	◇	◇	—	◇	◇
Pritesh Shah Chief Commercial Officer	◇	—	◇	◇	◇	—	◇	◇
Francis Leonard President, CNS Cancers US	◇	—	◇	◇	◇	—	◇	◇
Asaf Danziger Chief Executive Officer	◇	—	—	◇	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Ashley Cordova Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Frank Leonard Executive Vice President, President Novocure US	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Ashley Cordova Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Frank Leonard Executive Vice President, President Novocure US	◇	—	◇	◇	◇	—	◇	◇
Uri Weinberg Chief Innovation Officer	◇	—	◇	◇	◇	—	◇	◇
Barak Ben-Arye General Counsel	◇	—	◇	◇	◇	—	◇	◇
Asaf Danziger Chief Executive Officer	◇	—	—	—	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Ashley Cordova Former Chief Executive Officer Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
Frank Leonard Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Christoph Brackmann Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Uri Weinberg Chief Medical and Innovation Officer	◇	—	◇	◇	◇	—	◇	◇
Nicolas Leupin Former Chief Medical Officer Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
Michael Puri Chief Human Resources Officer	◇	—	◇	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Ashley Cordova	PSU	◇	◇	◇	—	◇	—	◇
Ashley Cordova	RSU	◇	—	—	◇	—	—	◇
Ashley Cordova	OPTION	◇	—	—	◇	—	◇	◇
Christoph Brackmann	PSU	◇	◇	◇	—	◇	—	◇
Christoph Brackmann	RSU	◇	—	—	◇	—	—	◇
Christoph Brackmann	OPTION	◇	—	—	◇	—	◇	◇
Frank Leonard	RSU	◇	—	—	◇	—	—	◇
Frank Leonard	PSU	◇	◇	◇	—	◇	—	◇
Frank Leonard	RSU	◇	—	—	◇	—	—	◇
Frank Leonard	OPTION	◇	—	—	◇	—	◇	◇
Michael Puri	PSU	◇	◇	◇	—	◇	—	◇
Michael Puri	RSU	◇	—	—	◇	—	—	◇
Michael Puri	OPTION	◇	—	—	◇	—	◇	◇
Nicolas Leupin	RSU	◇	—	—	◇	—	—	◇
Nicolas Leupin	PSU	◇	◇	◇	—	◇	—	◇
Nicolas Leupin	OPTION	◇	—	—	◇	—	◇	◇
Uri Weinberg	OPTION	◇	—	—	◇	—	◇	◇
Uri Weinberg	PSU	◇	◇	◇	—	◇	—	◇
Uri Weinberg	RSU	◇	—	—	◇	—	—	◇

Fiscal 2022, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Michael Puri	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/3/2035
Frank Leonard	Option	◇	—	◇	2/26/2034
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	10/31/2032
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/27/2033
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	3/3/2035
	Option	◇	—	◇	2/29/2032
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Uri Weinberg	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	2/27/2033
	Option	◇	—	◇	2/29/2032
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/26/2034
	PSU	◇	◇	—	—
	Option	◇	—	◇	3/3/2035
	RSU	◇	◇	—	—
Nicolas Leupin	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	3/3/2035
Ashley Cordova	RSU	◇	◇	—	—
	Option	◇	—	◇	2/26/2034
	Option	◇	—	◇	3/3/2035
	Option	◇	—	◇	2/27/2033
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/29/2032
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
Christoph Brackmann	Option	◇	—	◇	11/3/2034
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	3/3/2035

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Ashley Cordova

Former Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance cash amount	◇
Equity acceleration on change in control	◇
Excise tax treatment	◇
Non-compete period	◇
Non-solicit period	◇

Christoph Brackmann

Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance base	◇
Severance cash amount	◇
Change-in-control multiple	◇
Excise tax treatment	◇
Non-compete period	◇
Non-solicit period	◇

Frank Leonard

Chief Executive Officer · Employment agreement

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇

Michael Puri

Chief Human Resources Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Excise tax treatment	◇
Non-compete period	◇
Non-solicit period	◇

Nicolas Leupin

Former Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Excise tax treatment	◇
Non-compete period	◇
Non-solicit period	◇

Uri Weinberg

Chief Medical and Innovation Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Excise tax treatment	◇
Non-compete period	◇
Non-solicit period	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Asaf Danziger	◇	◇	—	—	—	◇	◇
William Doyle Board chair	◇	—	—	—	—	◇	◇
William Vernon Lead independent director	◇	◇	◇	—	—	—	◇
Martin Madden	◇	—	◇	—	—	—	◇
Jeryl Hilleman	◇	◇	◇	—	—	—	◇
Timothy Scannell	◇	◇	◇	—	—	—	◇
Kinyip Gabriel Leung	◇	◇	◇	—	—	—	◇
Kristin Stafford	◇	◇	◇	—	—	—	◇
David Hung	◇	◇	◇	—	—	—	◇
Allyson Ocean	◇	◇	◇	—	—	—	◇

Frank Leonard and Ashley Cordova served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Lead independent director premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Stock ownership guideline: Non-Employee Directors are expected to own Ordinary Shares of our Company having a value equal to at least three times the annual cash retainer.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

10x Genomics, Inc. TXG
Align Technology ALGN
Alnylam Pharmaceuticals, Inc. ALNY
CRISPR Therapeutics AG CRSP
Exact Sciences Corporation EXAS
Exelixis, Inc EXEL
Incyte Corporation INCY
Inspire Medical Systems, Inc. INSP
Insulet Corporation PODD
iRhythm Technologies IRTC
Teladoc Health, Inc. TDOC
Zai Lab Limited ZLAB

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	June 3, 2026	=	◇	◇	◇
2024	June 4, 2025	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Frank Leonard (Chief Executive Officer), FY2025 total compensation $6,975,329 (base salary $570,000) [exec_comp, SEC accession 0001645113-26-000033, filed 2026-04-20]

What this page does not include

Everything above is a fact NovoCure disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where NovoCure sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $499

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

365 figures on this page: 363 cited to the filing that reported them, 2 calculated from figures it prints.

363 cited to the filing

2 calculated from the filing

Documents cited

8-K, filed June 5, 2026
0001645113-26-000050
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 20, 2026
0001645113-26-000033
2025 DIRECTOR COMPENSATION · 2025 Director Compensation Table · 2025 Grants of Plan-Based Awards · 2025 Summary Compensation Table · and 3 more sections
8-K, filed June 6, 2025
0001645113-25-000011
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 21, 2025
0001645113-25-000005
2024 Summary Compensation Table
DEF 14A, filed April 22, 2024
0001645113-24-000011
2023 Summary Compensation Table
DEF 14A, filed April 24, 2023
0001645113-23-000034
2022 Summary Compensation Table

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “NovoCure executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/NVCR (accessed 2026).

Short form: data: Velarion

The paid brief for NovoCure

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $499 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

6 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/NVCR/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="NovoCure executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about NovoCure and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & Diagnostics CEO pay ratio — MedTech & Diagnostics Say-on-pay support — MedTech & Diagnostics

Peers NovoCure discloses

The companies named in NVCR's own disclosed peer group.

10x Genomics, Inc.Align Technology Alnylam Pharmaceuticals, Inc.CRISPR Therapeutics AG Exact Sciences Corporation Exelixis, Inc Incyte Corporation Inspire Medical Systems, Inc.Insulet Corporation iRhythm Technologies Teladoc Health, Inc.Zai Lab Limited

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on NovoCure

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Chief executive pay ratio

Velarion Pro: every company page, peer tools and exports, one seat

What this page does not include

Citations

Documents cited

The paid brief for NovoCure

MedTech & Diagnostics rankings

Peers NovoCure discloses

Terms on this page